Waters Corporation’s cover photo
Waters Corporation

Waters Corporation

Biotechnology Research

Milford, MA 283,656 followers

Waters is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science

About us

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.

Website
http://www.waters.com
Industry
Biotechnology Research
Company size
10,001+ employees
Headquarters
Milford, MA
Type
Public Company
Specialties
UPLC, HPLC, Chromatography, Mass Spectrometry, Informatics, Thermal Imaging, Chemistry, Analytical Standards & Reagents, Data Integrity, and Specialty Measurement

Locations

Employees at Waters Corporation

Updates

  • New Podcast Alert – The Evolution of Gel Permeation Chromatography (GPC) In the latest episode of Chromatography Life Podcast, host Neil Lander talks with Larry Meeker, a Gel Permeation Chromatography (GPC) expert with 27+ years at Waters, about what’s changed—and what matters most today. Key insights: • Advances in GPC instrumentation and column chemistry • The growing importance of chromatography software • Why hands‑on experience still drives successful GPC workflows Listen Now: https://bit.ly/3D1ZnlP

    • No alternative text description for this image
  • At Waters, our strength comes from the diverse backgrounds, perspectives, and experiences that shape our global team. Innovation happens when different viewpoints and ways of thinking come together, enabling us to solve complex scientific challenges. Earlier this year, our combination with the BD Biosciences and Diagnostic Solutions businesses expanded that perspective further, bringing new capabilities, talent, and insight from teams working across more countries and communities. This broader view strengthens how we develop technologies, understand our customers’ needs, and advances the science that impacts us all. On World Day for Cultural Diversity for Dialogue and Development, we celebrate the richness of the world’s cultures as critical enablers of not only success but the collective impact we create together. Photos were taken during global celebrations following the completion of the combination.

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • It has been a meaningful week for Waters Corporation at the World Health Assembly, Geneva, Switzerland. Our presence reflects both continuity and momentum, building on the strong legacy of BD Diagnostic Solutions while bringing the full strength of Waters’ analytical science to global health policy conversations. Together, our combined expertise elevates how we engage, lead with science, and contribute to evidence‑based decision‑making in this space. We valued the opportunity to listen, learn, and connect with partners shaping the future of health systems worldwide. We’re proud of how this next chapter is taking shape, and excited about the role our heightened scientific leadership can play in advancing global health.

    • No alternative text description for this image
  • Matthew Lauber, Senior Director of Bioseparations at Waters Corporation, was featured in The Medicine Maker, talking about the analysis and characterization of GLP-1 receptor agonists. "GLP-1 peptides can be challenging to work on because of their complexity, structural modifications, varying bioavailability, and conjugation chemistries, combined with challenging solubility and stability profiles", said Matt, during an interview last year. "It is essential to know about each atom ahead of investigational new drug filings, during first-in-human clinical studies, upon seeking approval to go to market, and when completing batch release testing on a commercial product." Read the full interview here: https://bit.ly/49LOOk9 Be the first to know what's new: https://bit.ly/3RbRTDQ

    • No alternative text description for this image
  • New WHO guidelines advocate for HPV extended genotyping to pinpoint riskier HPV types for smarter cervical cancer screening and better care. HPV extended genotyping helps clinicians better identify carcinogenic strains, and so these guidelines mark a major step forward toward more precise care and better outcomes for women everywhere. BD Onclarity™ HPV Assay, the first clinically validated HPV assay with extended genotyping and now part of the Waters Advanced Diagnostics portfolio, is helping move the world closer to eliminating cervical cancer. Jeff Andrews, Vice President, Medical Affairs, Waters Advanced Diagnostics explains more in his article here: https://bit.ly/3RzPvH7

  • Join Mike Morris at the Waters ASMS Users Meeting as he explores how advances in mass spectrometry technology and methods are transforming what we can measure across proteomics, metabolomics, and clinical applications. Discover insights on: • More reliable biomarker discovery for earlier disease detection • Improved development and quality control of biotherapeutics • Faster, high-resolution insights into complex biological systems • Stronger foundations for precision medicine and personalized care This half-day event is free to attend. View the full agenda and register: https://bit.ly/4tlzYrJ

    • No alternative text description for this image
  • Congratulations to Amol Chaubal, Senior Vice President and Chief Financial Officer of Waters Corporation, for being honored as the CFO of the Year in the large public company category by the Boston Business Journal. This award highlights Amol’s non-traditional background as a chemical engineer and recognizes the value his technical experience brings to his financial leadership of Waters, a global leader in life sciences and diagnostics. Read more here: https://bit.ly/4u5Woyl

    • No alternative text description for this image
  • This week, the Waters teams have been busy with three concurrent events in Boston: the TIDES USA Congress, the Protein & Antibody Engineering Summit (PEGS), and the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, to connect directly with the scientists advancing today’s most complex therapeutics. Talks and posters focused on generating data you can trust when molecules and modalities don’t behave simply or predictably. From oligonucleotides and peptides to monoclonal antibodies and emerging cell and gene therapies, the conversations centered on practical ways to better characterize complexity, improve reproducibility, and scale with confidence. With new tools launching soon, sign up to be the first to know more! GLP-1s: https://bit.ly/3RbRTDQ LNPs: https://bit.ly/4tAjrjF

    • No alternative text description for this image
  • Make your morning at ASMS 2026 count. Join the Waters Breakfast Seminars for exclusive access to expert-led sessions and early insights into the latest advances in mass spectrometry, before the show floor opens. The sessions will give you: • Practical takeaways that you can apply immediately • Perspectives from other leaders in the field • A smarter way to start your conference day Learn, connect, and stay ahead, without sacrificing your schedule. View the agenda and register to start your day right: https://bit.ly/3QStwuU

    • No alternative text description for this image

Affiliated pages

Similar pages

Browse jobs

Funding

Waters Corporation 2 total rounds

Last Round

Grant

US$ 6.0M

Investors

IDA Ireland
See more info on crunchbase